NCT Number: NCT02739568
Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA
The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy or treated by nCPAP but still complaining of EDS.
The secondary objectives of the study include assessing the long-term tolerance as well as the maintenance of efficacy of pitolisant given at 10, 20 or 40 mg per day during 39 weeks of Open Label Extension period and further investigating the co-variates or co-medications that affect the pharmacokinetics of pitolisant in the target population.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–100 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Specialised Hospital for Active Treatment of pneumo-phthisiatric diseases - Burgas" EOOD, Pneumology ward, Burgas, Bulgaria
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male and/or female outpatients aged from at least 18 years
- Patients complaining of EDS refusing to be treated by nCPAP therapy or having been submitted to nCPAP therapy for a minimum period of 3 months, and still complaining of EDS despite the efforts made beforehand to obtain an efficient nCPAP therapy
- Polysomnography performed (for patients submitted to nCPAP therapy - under nCPAP) between V1 and V2 or during the last 12 months with Apnea-Hypopnea Index (AHI): for patients without nCPAP therapy ≥ 15; for patients under nCPAP therapy less or equal to 10
- For patients submitted to nCPAP therapy: nCPAP ≥ 4 hours / day (compliance checked on the clock-time counter of the CPAP machine)
- Mini Mental State Examination (MMSE) ≥ 28
- Beck Depression Inventory - 13 items (BDI-13) score < 16 and item G (suicidal ideation) of BDI-13 = 0
- Body Mass Index (BMI )less or equal to 40 kg/m²
- Epworth Sleepiness Scale (ESS) ≥ 12
- Female patients with child-bearing potential using a medically accepted method of birth control (i.e. oral contraceptives of normal average dosage) agreeing to continue this method throughout the study, and during the month following treatment discontinuation, being negative to serum pregnancy test performed at the screening visit
- If specified by the investigator, the patient must be willing not to operate a car (if sleepy at wheel) or heavy machinery for the duration of the trial or as long as the investigator deems it clinically indicated. In addition, the patient should be willing to maintain during the study their usual behaviors which could affect their diurnal sleepiness (e.g. circadian rhythm, caffeine consumption, nocturnal sleep duration)
- Patients having signed and dated the informed consent form
Exclusion criteria
- Patients suffering from chronic severe insomnia in accordance with the International Classification of Sleep Disorders (ICSD 2005) without OSA
- Patients with co-existing narcolepsy (ICSD 2005), judged on clinical criteria
- Patients with sleep debt not due to OSA (according to the physician' s judgment)
- Patients with non-respiratory sleep fragmentation (restless leg syndrome…)
- Shift work, professional drivers
- Refusal from the patient to stop any current therapy for EDS or predictable risk for the patient to stop the therapy
- Patients suffering from a psychiatric disease
- Acute or chronic disease preventing the improvement assessment, e.g. severe chronic obstructive pulmonary disease (COPD)
- Current or recent (within one year) history of drug, alcohol, narcotic or other substance abuse or dependence
- Any significant serious abnormality of the cardiovascular system, e.g. recent myocardial infarction, angina, hypertension or dysrhythmias (within the previous 6 months), Electrocardiogram Fridericia corrected QT interval higher than 450 ms, history of left ventricular hypertrophy or mitral valve prolapse
- Severe co-morbid medical or biological conditions that may jeopardize study participation at the discretion of the investigator (particularly in the cardiovascular system and the instable diabetes)
- Positive serology tests (HIV, HCV and HBsAg)
- Pregnant or breast-feeding women
- Women with child-bearing potential and no efficient birth-control method
- Patients unable to understand the study protocol
- Patients with suspected or known hypersensitivity to study medication
- Patients with a dominant arm deficiency impeding the achievement of the tests
- Patients using a prohibited medication
- Congenital galactose poisoning, glucose and galactose malabsorption, deficit in lactase
- Patients participating in another study or being in a follow-up period for another study
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Epworth sleepiness scale (ESS)
Time frame: at weeks 12 and 52
Change from Baseline of ESS
Secondary outcomes
-
Percentage of ESS responders
Time frame: at weeks 12 and 52
Percentage of ESS responders
-
Reduction of sleepiness and sleep episodes on the sleep diary
Time frame: at weeks 12 and 52
Reduction of sleepiness and sleep episodes
-
Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test
Time frame: at weeks 12 and 52
Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test
-
European Quality of Life Questionnaire (EQ-5D)
Time frame: at weeks 12 and 52
EQ-5D improvement (mobility, self-care, usual activities, pain/discomfort and anxiety/depression)
-
Leeds Sleep Evaluation Questionnaire (LSEQ)
Time frame: at weeks 12 and 52
LSEQ improvement (changes in sleep and next morning behaviour during disease/pharmacological investigations)
-
The Pichot Fatigue Scale
Time frame: at weeks 12 and 52
Pichot Fatigue scale improvement (assessment of the level of discomfort caused by a state of fatigue)
-
Trail Making Test parts (A and B)
Time frame: at weeks 12 and 52
TMT test improvement
-
Improvement in Clinical Global Impression (CGI)
Time frame: at weeks 12 and 52
CGI improvement (patient progress and treatment response over time)
-
Aggregate Z-score of secondary endpoints.
Time frame: at weeks 12 and 52
Aggregate Z-score of secondary endpoints improvement
Sponsors and collaborators
Lead sponsor
Bioprojet
Other
Registry information
Official study title
Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
Acronym: HAROSA3
Important dates
- Study start
- 2016
- Primary completion
- 2020
- Study completion
- 2020
- First posted
- Apr 15, 2016
- Registry last updated
- Jul 8, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
NCT04789174
Apnea, Disorders of Excessive Somnolence
Los Angeles, California, United States
View Trial DetailsBF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS
NCT01071876
Apnea, Disorders of Excessive Somnolence
Grenoble, France
View Trial DetailsBF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.
NCT01072968
Apnea, Disorders of Excessive Somnolence
Grenoble, France
View Trial DetailsA Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)
NCT06103825
Apnea, Disorders of Excessive Somnolence
Shanghai, Shanghai Municipality, China
View Trial Details